Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome
This study has been completed.
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes
Sponsored by: Liposome
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002019
  Purpose

To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.


Condition Intervention
Meningitis, Cryptococcal
HIV Infections
Drug: Amphotericin B, Lipid-based
Drug: Amphotericin B

Study Type: Interventional
Study Design: Treatment, Dose Comparison, Safety Study
Official Title: Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

Resource links provided by NLM:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Intravenous pentamidine for treatment of Pneumocystis carinii pneumonia (PCP) but not for prophylaxis.

Patients must have the following:

  • Meet the CDC criteria for diagnosis of AIDS.
  • Confirmed episode of acute cryptococcal meningitis.
  • Informed consent of the patient or guardian prior to entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans.
  • History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B.
  • Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study.

Concurrent Medication:

Excluded:

  • Corticosteroids.
  • Salicylates or other drugs known to interfere with prostaglandin synthesis except as specified in protocol.
  • Zidovudine.
  • Investigational agents.
  • Interferon.
  • Interleukin-2 (IL-2).
  • Steroids.
  • Isoprinosine.
  • Intrathecal Amphotericin B.
  • Intravenous Pentamidine PCP prophylaxis (only treatment).

Patients with the following are excluded:

  • Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans.
  • History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B.
  • Inability to obtain appropriate follow-up visits.
  • Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study.

Prior Medication:

Excluded within 4 weeks of study entry:

  • Amphotericin B.
  • Excluded within 2 weeks of study entry:
  • Any other experimental drug.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002019

Locations
United States, California
Harbor - UCLA Med Ctr
Torrance, California, United States, 90502
United States, Connecticut
Dr Thomas Patterson
New Haven, Connecticut, United States, 06510
United States, District of Columbia
Walter Reed Army Med Ctr
Washington, District of Columbia, United States, 203075001
United States, Illinois
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, United States, 60612
United States, Maryland
Natl Naval Med Ctr
Bethesda, Maryland, United States, 20889
United States, Massachusetts
Univ Hosp
Boston, Massachusetts, United States, 02118
United States, New Jersey
East Orange Veterans Administration Med Ctr
East Orange, New Jersey, United States, 07018
Saint Michael's Med Ctr
Newark, New Jersey, United States, 07102
United States, New York
Mount Sinai Med Ctr / Jack Martin Fund Clinic
New York, New York, United States, 10029
Saint Luke's - Roosevelt Hosp Ctr
New York, New York, United States, 10025
Dr Dorothy Friedberg
New York, New York, United States, 10016
New York Univ Med Ctr
New York, New York, United States, 10016
Cornell Univ Med College
New York, New York, United States, 10021
Beth Israel Med Ctr / Peter Krueger Clinic
New York, New York, United States, 10003
Mount Sinai Med Ctr
New York, New York, United States, 10029
United States, Pennsylvania
Buckley Braffman Stern Med Associates
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Univ TX Galveston Med Branch
Galveston, Texas, United States, 77550
Audie L Murphy Veterans Administration Hosp
San Antonio, Texas, United States, 78284
United States, Utah
Univ of Utah School of Medicine
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Liposome
  More Information

Publications:
al-Haddadin D, Fan-Havard P, Boghossian J, Marton R, Vincent-Graber D, Dungo L, Eng RH, Johnson ES. Amphotericin B-lipid complex (ABLC) in treatment of cryptococcal meningitis in AIDS. Int Conf AIDS. 1992 Jul 19-24;8(2):B109 (abstract no PoB 3132)

Study ID Numbers: 051A
Study First Received: November 2, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00002019     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Meningitis
Liposomes
Cryptococcosis
Acquired Immunodeficiency Syndrome
Amphotericin B
Chemistry, Pharmaceutical

Study placed in the following topic categories:
Abelcet
Anti-Infective Agents
Amphotericin B
Sexually Transmitted Diseases, Viral
Meningitis, Fungal
Acquired Immunodeficiency Syndrome
Central Nervous System Diseases
Liposomal amphotericin B
Immunologic Deficiency Syndromes
Meningitis
Virus Diseases
Anti-Bacterial Agents
Mycoses
Central Nervous System Infections
HIV Infections
Antifungal Agents
Sexually Transmitted Diseases
Meningitis, Cryptococcal
Central Nervous System Fungal Infections
Cryptococcosis
Retroviridae Infections

Additional relevant MeSH terms:
Abelcet
Anti-Infective Agents
Antiprotozoal Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Liposomal amphotericin B
Infection
Meningitis
Anti-Bacterial Agents
Mycoses
Antiparasitic Agents
Pathologic Processes
Antifungal Agents
Therapeutic Uses
Syndrome
Antibiotics, Antifungal
Meningitis, Cryptococcal
Amebicides
Central Nervous System Fungal Infections
Retroviridae Infections
Amphotericin B
RNA Virus Infections
Meningitis, Fungal
Disease
Immune System Diseases
Acquired Immunodeficiency Syndrome
Nervous System Diseases
Central Nervous System Diseases
Pharmacologic Actions
Immunologic Deficiency Syndromes

ClinicalTrials.gov processed this record on September 02, 2009